Travere Therapeutics, Inc. TVTX Q1 2025 earnings
Reported May 1, 2025 · After market close
Revenue$81.7MMiss by $7.1M
EPS-$0.47Beat by $0.08
Revenue estimate$88.8M
EPS estimate-$0.55
Next report
Aug 5, 2026 (In 1 week)Revenue estimate$159.2M
EPS estimate-$0.14
Financials
Q1 2025Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
Ask the moment Travere Therapeutics, Inc. reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Travere Therapeutics, Inc. report Q1 2025 earnings?
- Travere Therapeutics, Inc. (TVTX) reported Q1 2025 earnings on May 1, 2025 after market close.
- What were Travere Therapeutics, Inc.'s Q1 2025 revenue and EPS?
- Travere Therapeutics, Inc. reported revenue of $81.7M and eps of $-0.47 for Q1 2025.
- Did Travere Therapeutics, Inc. beat estimates in Q1 2025?
- Revenue missed the consensus estimate of $88.8M by $7.1M. EPS beat the consensus estimate of $-0.55 by $0.08.
- How did Travere Therapeutics, Inc.'s Q1 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 97.5% from $41.4M a year earlier and eps grew 73.3% from $-1.76.
- Where can I find Travere Therapeutics, Inc.'s Q1 2025 SEC filings?
- You can read the 10-Q periodic report (0001438533-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.